Search
Menu
Home
HTB
2000
December
December 2000
Contents
Conference reports
Fifth International Congress on Drug Therapy in HIV Infection, 22-26 October 2000, Glasgow, UK
Treatment strategies in 2000: planning first-line (and therefore, second-line) therapy
When should HAART be started?
MDR resistance transmission increases in the UK
Interferon-gamma treatment in azole-resistant oropharyngeal candidiasis
Further reports of avascular necrosis (AVN) and changes in bone mineral density (BMD)
Clinical issues arising from a single treatment interruption
A review of new anti-HIV drugs in development
Antiretroviral therapy in children, women and intravenous drug users
Treatment of HIV+ subjects co-infected with hepatitis B or C: safety and efficacy comparison of ABT 378/r versus nelfinavir from a phase III blinded randomised clinical trial
Interferon-alpha and ribavarin therapy for hepatitis C in HIV coinfected patients
Lack of significant viral load alterations of hepatitis B virus (HBV) and hepatitis C virus (HCV) during treatment with interleukin-2 and HAART
Child protection issues around starting efavirenz in a mother on maintenance methadone
Structured treatment interruptions
Adherence and HAART: unique approaches to evaluating and improving adherence discussed
Reports on lipodystrophy and metabolic complications
Opportunistic infections in the HAART era
Antiretrovirals
Importance of intensive adherence support for people with HIV-related neurological symptoms
Efavirenz side effects become long-term for over one in three
ABT-378/r oral formulation available in UK
Trimeris, Roche to begin phase III pivotal trials of T-20 HIV fusion inhibitor
Women's health
Women initiate highly active antiretroviral therapy later than men
Association of vitamin A deficiency With cervical squamous intraepithelial lesions in HIV-positive women
Side effects
Adverse effects of antiretroviral therapy
Basic science and immunology
Antiretrovirals do not independently affect T-cell count in HIV negative subjects
Zidovudine-didanosine coexposure potentiates DNA incorporation of zidovudine and mutagenesis in human cells
HLA-DR integrates with HIV-1 at chronic disease stage, may raise infectivity
Vaccines and microbicides
Immune Response Corporation tried to block report on failure of Remune
Other news
FDA meeting on approving immune therapies: background and comment
HIV seroprevalence by anonymous testing in patients with mycobacterium tuberculosis and in tuberculosis contacts
HIV-1 Immunogen fails to extend HIV progression-free survival
On the web
AIDS-related lymphoma
PDFs
Volume 1 Number 8 November / December 2000 PDF
HTB RSS
Early access
Vaccination is effective in limiting mpox progression – but lower efficacy in people living with HIV
27 May 2025
US update guidelines for statin use in people living with HIV
26 May 2025
HIV activists in the US call for action in JID and Zachie Achmet brings South African perspective in the Lancet
26 May 2025
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025
All early access reports
Current issues
May 2025
April 2025
March 2025
Back issues
Special report
Scientific, legal and ethical crisis from halting ongoing NIH studies: TAG statement
22 May 2025
More from HTB
Conference reports
Conference shortcuts
Articles by subject
PDFs
Subscribe
HTB homepage
Home
i-Base homepage
Donate